Relacorilant

Relacorilant
Clinical data
Synonyms CORT-125134
Routes of
administration		 By mouth
Drug class Antiglucocorticoid
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
Formula C27H22F4N6O3S
Molar mass 586.566 g/mol
3D model (JSmol)

Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome.[1] It is also under development for the treatment of solid tumors and alcoholism.[1][2] The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor.[1] As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown.[1]

See also

References

  1. 1 2 3 4 http://adisinsight.springer.com/drugs/800041622
  2. ↑ Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF (2017). "High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer". Gynecol. Oncol. 146 (1): 153–160. doi:10.1016/j.ygyno.2017.04.012. PMID 28456378.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.